Zacks Investment Research upgraded shares of GENFIT S A/ADR (NASDAQ:GNFT) from a hold rating to a buy rating in a research note released on Wednesday morning, Zacks.com reports. They currently have $18.00 price objective on the stock.

According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “

Several other analysts have also weighed in on GNFT. Stifel Nicolaus began coverage on shares of GENFIT S A/ADR in a research note on Tuesday, June 25th. They set a hold rating for the company. HC Wainwright lowered their target price on shares of GENFIT S A/ADR to $72.00 and set a buy rating for the company in a research note on Monday, April 22nd. Svb Leerink began coverage on shares of GENFIT S A/ADR in a research note on Wednesday, April 24th. They set an outperform rating and a $58.00 target price for the company. Barclays began coverage on shares of GENFIT S A/ADR in a research note on Monday, April 22nd. They set an overweight rating and a $55.00 target price for the company. Finally, Leerink Swann began coverage on shares of GENFIT S A/ADR in a research note on Wednesday, April 24th. They set an outperform rating and a $25.47 target price for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of Buy and a consensus price target of $45.69.

Shares of NASDAQ:GNFT opened at $15.79 on Wednesday. The stock has a fifty day moving average of $18.04. GENFIT S A/ADR has a 12-month low of $14.91 and a 12-month high of $26.25.

Institutional investors and hedge funds have recently made changes to their positions in the company. Boussard & Gavaudan Investment Management LLP acquired a new position in shares of GENFIT S A/ADR during the second quarter valued at $199,000. Morgan Stanley boosted its holdings in shares of GENFIT S A/ADR by 24.4% during the second quarter. Morgan Stanley now owns 10,700 shares of the company’s stock valued at $211,000 after acquiring an additional 2,100 shares during the period. Dean Capital Investments Management LLC acquired a new position in shares of GENFIT S A/ADR during the first quarter valued at $650,000. One68 Global Capital LLC acquired a new position in shares of GENFIT S A/ADR during the first quarter valued at $270,000. Finally, Balyasny Asset Management LLC acquired a new position in shares of GENFIT S A/ADR during the second quarter valued at $699,000. 14.69% of the stock is owned by institutional investors.

GENFIT S A/ADR Company Profile

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Further Reading: Cost of Capital Explained

Get a free copy of the Zacks research report on GENFIT S A/ADR (GNFT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GENFIT S A/ADR (NASDAQ:GNFT)

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.